Skip to content
ESPT
MARKETS / NYSE / Health care / Pharmaceuticals / TEVA
NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Teva Pharmaceutical Industries Ltd. TEVA

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$17.3B
▲ 4.3% YoY
$1.4B
$1.1B
▲ 53.3% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Teva Pharmaceutical Industries Limited innovates in the fields of neuroscience and immunology while providing complex generic medicines, biosimilars and pharmacy brands worldwide. It operates worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets, and its global network comprises approximately 34,000 employees across 57 markets. It operates its business through three segments: United States, Europe and International Markets. Its Europe segment includes the European Union, the United Kingdom and certain other European countries. Its International Markets segment covers a substantial portion of the global pharmaceutical industry, including more than 35 countries. In 2025, it produced approximately 66 billion tablets and capsules, and approximately 600 million sterile units. Teva was incorporated in Israel on February 13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901.

Written from the business description in TEVA PHARMACEUTICAL INDUSTRIES LIMITED's annual report to the U.S. Securities and Exchange Commission, filed 3 February 2026. Every sentence was checked against that document before publication.

Growth

USD 17.3B
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 17.3 · Net income 1.4
10B20B-10B-20B
2007201020132018202120242025
Compound annual growth
+5.0%
+0.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +0.7% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

8 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 12.5% · Net 8.2%
10%20%-50%
200720172025
ROE
FY2025 · ROE 21.2%
10%20%-20%-40%-60%
200720172025
Three returns, three denominators.
Gross margin51.8%
Operating margin12.5%
Net margin8.2%
EBITDAUSD 2.6B

Each USD of equity produced 21 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 1.1
2B3B
200720172025
Net buybacks $B Dividends $B
FY2018 · Dividends 0.0 · Net buybacks ·
1B2BDividendsNet buybacks
2007200820092010201120122013201620172018
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 40.7B
EquityUSD 7.9B
CashUSD 3.6B
Gross debtUSD 1.8B
Net debtUSD -1.8B
Current ratio1.04×

The company holds more cash than debt.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
TEVA, 17-year financial record
Metric 20252024202320222021202020192018201720162013201220112010200920082007
Revenue $B17.316.515.814.915.916.716.918.321.921.920.320.318.316.116.111.19.4
Operating income $B2.2−0.30.4−2.21.7−3.6−0.4−1.6−17.52.21.62.23.13.92.41.12.4
EBITDA $B2.60.21.0−1.62.2−3.00.2−1.0−16.92.72.12.63.54.32.81.5◌
Income tax $B−0.20.7−0.0−0.60.2−0.2−0.3−0.2−1.90.5−0.0−0.10.10.30.20.20.4
Net income $B1.4−1.6−0.6−2.40.4−4.0−1.0−2.1−16.30.31.32.02.83.32.00.61.9
Free cash flow $B1.10.70.81.00.20.60.21.81.43.02.23.53.13.42.72.51.3
EPS, diluted $1.21−1.45−0.50−2.200.38−3.64−0.91−2.35−16.260.071.492.253.093.672.230.752.36
Dividend / sh $◌◌◌◌◌◌0.000.000.851.361.281.030.890.740.610.50◌
Payout %———————−1−639686442920266416
ROE %21.2−25.5−7.3−27.14.1−33.3−7.0−13.4−62.10.95.68.712.516.211.24.013.8
Shares out B◌◌◌◌◌◌◌◌◌◌◌◌◌0.940.920.89◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 81 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Two checks were skipped: the balance sheet is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2007

Share this section

Download image